Education
About Us
Working with TipRanks
Follow Us
Cellectis S.A. (CLLS)
:CLLS
CLLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $3.38
Previous CloseN/A
Volume129.50K
Average Volume (3M)592.72K
Market Cap
$98.81M
Enterprise Value$63.37M
Total Cash (Recent Filing)$451.89M
Total Debt (Recent Filing)$1.35M
Price to Earnings (P/E)―
Beta4.31
Next Earnings
May 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding72,093,636
10 Day Avg. Volume1,577,558
30 Day Avg. Volume592,717
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.90
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.52K
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$5.50Price Target Upside323.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cellectis SA News
PremiumCompany Announcements
Cellectis Reports 2024 Financial Results and Strategic Advances
PremiumCompany Announcements
Cellectis S.A. Earnings Call Highlights Strategic Growth
---
Bulls Say, Bears Say
Bulls Say
Clinical ProgramsCellectis is making substantial progress across its clinical programs following a pipeline overhaul and strategic investment by AZN.
Financial PerformanceCellectis reported 3Q24 revenue of $18.1M versus an estimate of $11.2M.
Strategic PartnershipsThe AstraZeneca research partnership is off to a strong start with three programs underway and meaningful revenues triggered to date.
Bears Say
Project PrioritizationUCART123 (AMELI-01 trial) is deprioritized.
Resource AllocationCellectis management has decided to focus their resources on the UCART22 and UCART20x22 programs, and are deprioritizing the development of UCART123 in AML.
---
Ownership Overview
―
Insiders
3.67% Mutual Funds
14.27% Other Institutional Investors
82.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLLS FAQ
What was Cellectis S.A.’s price range in the past 12 months?
Cellectis S.A. lowest stock price was $1.14 and its highest was $3.38 in the past 12 months.
What is Cellectis S.A.’s market cap?
Cellectis S.A.’s market cap is $98.81M.
When is Cellectis S.A.’s upcoming earnings report date?
Cellectis S.A.’s upcoming earnings report date is May 07, 2025 which is in 44 days.
How were Cellectis S.A.’s earnings last quarter?
Cellectis S.A. released its earnings results on Mar 13, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.185 by $0.015.
Is Cellectis S.A. overvalued?
According to Wall Street analysts Cellectis S.A.’s price is currently Undervalued.
Does Cellectis S.A. pay dividends?
Cellectis S.A. does not currently pay dividends.
What is Cellectis S.A.’s EPS estimate?
Cellectis S.A.’s EPS estimate is -0.15.
How many shares outstanding does Cellectis S.A. have?
Cellectis S.A. has 72,093,636 shares outstanding.
What happened to Cellectis S.A.’s price movement after its last earnings report?
Cellectis S.A. reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.185. Following the earnings report the stock price went down -3.876%.
Which hedge fund is a major shareholder of Cellectis S.A.?
Among the largest hedge funds holding Cellectis S.A.’s share is Bpifrance SA. It holds Cellectis S.A.’s shares valued at 0.
---
Cellectis SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (323.08% Upside)
$5.50 (323.08% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.61%
12-Months-Change
Fundamentals
Return on Equity
-34.08%
Trailing 12-Months
Asset Growth
17.44%
Trailing 12-Months
Company Description
Cellectis S.A.
Cellectis SA is a clinical-stage biopharmaceutical company that operates in the field of gene-editing technology. Founded in 1999 and headquartered in Paris, France, the company focuses on developing immunotherapies based on gene-edited allogeneic CAR-T cells for the treatment of cancer. Using its proprietary TALEN technology and electroporation system, Cellectis aims to harness the power of the immune system to target and eradicate cancer cells, offering a potentially transformative approach to cancer treatment.
---
CLLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.Read More>---
CLLS Stock 12 Month Forecast
Average Price Target
$5.50
▲(323.08% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering CLLS
1 Year
1 Year Success Rate
9/26 ratings generated profit
1 Year Average Return
-23.18%
reiterated a buy rating 10 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of -23.18% per trade.
---